ABBV vs XCUR

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Exicure Inc. (XCUR) remains fundamentally unchanged as a dormant shell company with no active operations, clinical pipeline, or discernible business model as of May 2026. The company reports $0 revenue and continues to incur net losses, eroding its critically low cash position of $2.5 million. While still listed on NASDAQ, it faces regulatory risk with a delayed Q1 2026 10-Q filing. The previous E...